DE60040800D1 - Verminderung von angiogenese unter verwendung chondroitinsulfat abbauender enzyme - Google Patents

Verminderung von angiogenese unter verwendung chondroitinsulfat abbauender enzyme

Info

Publication number
DE60040800D1
DE60040800D1 DE60040800T DE60040800T DE60040800D1 DE 60040800 D1 DE60040800 D1 DE 60040800D1 DE 60040800 T DE60040800 T DE 60040800T DE 60040800 T DE60040800 T DE 60040800T DE 60040800 D1 DE60040800 D1 DE 60040800D1
Authority
DE
Germany
Prior art keywords
tumor
angiogenesis
decreases
formation
metastatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60040800T
Other languages
English (en)
Inventor
Elizabeth M Denholm
Yong-Qing Lin
Paul J Silver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Application granted granted Critical
Publication of DE60040800D1 publication Critical patent/DE60040800D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60040800T 1999-11-17 2000-11-17 Verminderung von angiogenese unter verwendung chondroitinsulfat abbauender enzyme Expired - Fee Related DE60040800D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16595799P 1999-11-17 1999-11-17
PCT/US2000/031663 WO2001035977A2 (en) 1999-11-17 2000-11-17 Attenuation of tumor growth, metastasis and angiogenesis by use of chondroitin sulfate degrading enzymes

Publications (1)

Publication Number Publication Date
DE60040800D1 true DE60040800D1 (de) 2008-12-24

Family

ID=22601193

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60040800T Expired - Fee Related DE60040800D1 (de) 1999-11-17 2000-11-17 Verminderung von angiogenese unter verwendung chondroitinsulfat abbauender enzyme

Country Status (7)

Country Link
EP (1) EP1231935B1 (de)
AT (1) ATE413886T1 (de)
AU (1) AU783222B2 (de)
CA (1) CA2414185A1 (de)
DE (1) DE60040800D1 (de)
ES (1) ES2319857T3 (de)
WO (1) WO2001035977A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781600B2 (en) * 1999-12-02 2005-06-02 Biomarin Pharmaceutical Inc. Attenuation of fibroblast proliferation
CN1553952A (zh) 2001-08-13 2004-12-08 ��ѧ�о��� 促进神经组织修复的材料和方法
DE60334220D1 (de) 2002-06-03 2010-10-28 Massachusetts Inst Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
CA2558984A1 (en) 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
WO2007049361A1 (ja) * 2005-10-27 2007-05-03 Stelic Corp. 肝線維化抑制剤
US20090202517A1 (en) * 2006-08-17 2009-08-13 Hiroyuki Yoneyama Agents for improving inflammatory bowel disease
JP4101276B2 (ja) * 2006-08-25 2008-06-18 株式会社ステリック再生医科学研究所 慢性閉塞性肺疾患改善剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508892A (ja) * 1993-11-17 1997-09-09 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼを用いる血管形成の阻害方法
US5997863A (en) * 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
WO1996008559A1 (en) * 1994-09-16 1996-03-21 Cardiac Crc Nominees Pty. Ltd. Glycosaminoglycan-degrading enzyme inhibition and resultant disease therapies

Also Published As

Publication number Publication date
WO2001035977A3 (en) 2002-01-17
WO2001035977A2 (en) 2001-05-25
AU1620601A (en) 2001-05-30
AU783222B2 (en) 2005-10-06
EP1231935B1 (de) 2008-11-12
WO2001035977A9 (en) 2002-07-25
CA2414185A1 (en) 2001-05-25
EP1231935A2 (de) 2002-08-21
ES2319857T3 (es) 2009-05-14
ATE413886T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
ATE368731T1 (de) Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen
WO2001023592A3 (en) Methods for making recombinant proteins using apoptosis inhibitors
ATE344051T1 (de) Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren
Yahalom et al. Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase.
BR9608326A (pt) Fragmentos de angiostatina e angiostatina agregada e processos de uso.
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
MXPA01007765A (es) Metodos para inhibir el crecimiento de tumores en el cerebro.
IT1260468B (it) Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
DK0675951T3 (da) Enzym med endoglucanaseaktivitet
IL151032A0 (en) Integrin antagonists
DE50014190D1 (de) Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
DE69825904D1 (de) Mutante alpha-amylase mit zusätzlicher disulfidverbindung
ATE264385T1 (de) Wachstumsfaktoren und l-glutamin enthaltendes zellkulturmedium
DE60040800D1 (de) Verminderung von angiogenese unter verwendung chondroitinsulfat abbauender enzyme
ATE403714T1 (de) Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen
GB2181741B (en) Enhancement of plasminogen activator production using heparin or low molecular weight heparin and an endothelial growth factor
WO2000066732A3 (en) Laminin 8 and methods for its use
AU6291799A (en) Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
Bachrach Polyamines and neoplastic growth: stabilization of ornithine decarboxylase during transformation
NO20004393L (no) Anvendelse av CD137 for Õ fremme proliferering av perifere monocytter
NO20014815D0 (no) Fremstilling av pankreatisk prokarboksypeptidase B, isoformer og muteiner derav og deres anvendelse
Piédagnel et al. SV40 large-T oncogene inhibits transcription of perlecan-related proteoglycans but stimulates hyaluronan synthesis in a temperature-sensitive renal-tubule principal cell line
Kress et al. Altered serum α-d-mannosidase activity in mucolipidosis II and mucolipidosis III
Moczar et al. Modulation of proteoglycan metabolism by hydrocortisone and by growth factors in rhabdomyosarcoma cell lines of different metastatic potentials
PT1196606E (pt) Enzima litica

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee